Cargando…

Health outcomes, education, healthcare delivery and quality – 3052. IL-17, IL-18, TGF-beta and GMCSF levels in patients with allergic asthma: Its relation to omalizumab treatment

Detalles Bibliográficos
Autores principales:	Yalcin, Arzu Didem, Bisgin, Atil, Gorczynski, Reginald M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Allergy Organization 2013
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643731/ http://dx.doi.org/10.1186/1939-4551-6-S1-P221

Ejemplares similares

Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

IL-8, IL-10, TGF-β, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti-IgE Treatment
por: Yalcin, Arzu D., et al.
Publicado: (2012)

277 Serum Soluble Trail Levels in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

233 The Evaluation of Allergen Sensitivity in Allergic Rhinoconjunctivitis and Allergic Asthma Patients in Antalya, Turkey
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Mechanisims of asthma and allergic disease – 1066. Ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Pollen aero allergens and the climate in mediterranean region and allergen sensitivity in allergic rhinoconjunctivitis and allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Health outcomes, education, healthcare delivery and quality – 3038: The relation of sTRAIL levels and quality of life in omalizumab using severe persistent allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

278 Total Antioxidant Capacity, Hydrogen Peroxide, Malondialdehyde and Total Nitric Oxide Concentrations in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Environmental and occupational respiratory diseases – 1039. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Environmental and occupational respiratory diseases – 1062. The climate and aero allergens in Mediterranean region and allergen sensitivity in allergic rhinoconjuctivitis and allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

384 Jessner-kanoff Lymphocytic Infiltrate as a Side Effect of Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Mechanisims of asthma and allergic disease - 1088. Increased serum strail level in newly diagnosed stave-iv lung adenocarcinoma but not sqamous cell carcinoma, is correlated with age and smoking
por: Kargi, Aysegul, et al.
Publicado: (2013)

Allergic diseases of the skin and drug allergies – 2027. Successful treatment with intravenous immunoglobulin and prednisolone pulse therapy of toxic epidemal necrolysis and Stevens-Johnson Syndrome
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps
por: Bagnasco, Diego, et al.
Publicado: (2022)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Country-based report: the safety of omalizumab treatment in pregnant patients with asthma
por: GEMİCİOĞLU, Bilun, et al.
Publicado: (2021)

IL-10, IL-15, IL-17, and GMCSF levels in cervical cancer tissue of Tanzanian women infected with HPV16/18 vs. non-HPV16/18 genotypes
por: Vidal, Adriana C, et al.
Publicado: (2015)

Allergic Rhinitis and Its Relationship with IL-10, IL-17, TGF-β, IFN-γ, IL 22, and IL-35
por: Bayrak Degirmenci, P., et al.
Publicado: (2018)

IL-22 Is Deleterious along with IL-17 in Allergic Asthma but Is Not Detrimental in the Comorbidity Asthma and Acute Pneumonia
por: Goulart, Amanda, et al.
Publicado: (2023)

Dual Role of Th17 Cytokines, IL-17A,F, and IL-22 in Allergic Asthma
por: Schnyder, Bruno, et al.
Publicado: (2012)

The effects of climate and aero allergens changes in allergic rhinoconjunctivitis and allergic asthma patients in mediterranean region between 2011 and 2012
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

The IL-17 receptor IL-17RE mediates polyIC-induced exacerbation of experimental allergic asthma
por: Vella, Giovanna, et al.
Publicado: (2020)

TLR9–IL-2 axis exacerbates allergic asthma by preventing IL-17A hyperproduction
por: Murakami, Yusuke, et al.
Publicado: (2020)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab in symptomatic therapy of laryngeal oedema and urticaria attacts in a patient with post operative pulmonary carsinoid tumor
por: Yalcin, Arzu Didem, et al.
Publicado: (2015)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Rhinovirus inhibits IL-17A and the downstream immune responses in allergic asthma
por: Graser, A, et al.
Publicado: (2016)

Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell–cell interactions
por: Wen, Qian, et al.
Publicado: (2016)

Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers
por: Celik, Betül, et al.
Publicado: (2013)

481 Differences in Humoral and Cellular Immunity in Young and Old Individuals
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Basic and clinical immunology – 3031. The correlation between serum protemics patterns of sTRAIL and CXCL8 with FDG-PET/CT findings in bevacizumab treated colon cancers
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Effect of the anti-IL-17 antibody on allergic inflammation in an obesity-related asthma model
por: Liang, Lin, et al.
Publicado: (2018)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Levofloxacin Induced Toxic Epidermal Necrolysis: Successful Therapy with Omalizumab (Anti-IgE) and Pulse Prednisolone
por: Uzun, Rusen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tpuknmhoacatiashf0jq5h5hvp